logo
Trade war means $2 trillion world GDP hit: Global outlook

Trade war means $2 trillion world GDP hit: Global outlook

Bloomberg4 days ago
Tariffs take 2026 global GDP forecast down to 2.7%
Tariffs are a negative for growth, they act like a tax hike. We have lowered our 2025 GDP forecast for the US to 1.5% from 2.1% in December. For China, front loading of exports will deliver a short-term boost that keeps 2025 growth buoyant. But with US tariffs up by about 30ppts, we've lowered our 2026 China growth call to 4.4%, from 5.6%. China accounts for about half of the downgrade to our global GDP forecast by the end of 2027.
For the world as a whole, we've nudged down our 2025 GDP forecast to 3% from our December call of 3.1%. That would be a slowdown from 3.2% growth in 2024 and some way below the pre-Covid run rate of 3.4%. Looking further ahead, and assuming tariffs climb a little from where they are now, we see global growth slowing further, to 2.7% in 2026.
Tariffs inflationary for US, disinflationary for everyone else
For the US, forecasting the impact of tariffs on inflation is not straightforward. Higher tariffs push import costs up. Margin compression for distributors and retailers reduces the pass-through to final consumers. Weaker growth is also disinflationary. Put the pieces together, and we have raised our forecast for US core PCE to 3.0% from 2.6% – a more modest increase than many on the street as we anticipate margin compression taking more of the strain.
For most of the rest of the world, the drag on growth and impact of Chinese goods seeking alternative markets are the dominant forces and so the impact of Trump's tariffs is disinflationary. We see global inflation ending 2025 at 3.2%, down from 5.1% at the end of 2024 and on a path to 2.7% at the end of 2026.
Slower global growth, falling inflation mean rate cuts ahead
The impact of the trade war on growth and inflation differs across economies. The potential for inflationary consequences is keeping the Fed in wait-and-see mode. For the People's Bank of China, the hit to external demand keeps the dial tilted toward easing. Weaker growth and disinflation as Chinese goods seek new markets both make the European Central Bank likely to cut again. In the UK, which has struck a (narrow) deal with the US, domestic issues, not tariffs, are the primary focus of monetary policy.
We anticipate 25 basis points of cuts this year from the Fed, followed by 150 bps next year as Chair Powell's successor plays catch-up. For the world as a whole, we anticipate the GDP-weighted central bank rate falling to 5% at end 2025, down from 6.1% at end 2024 and on a path to 4% at end 2026.
Consumer-led slowdown is biggest risk to the US outlook
Store shelves are stocked. Inflation is benign. People have jobs. And consumer dollars are flowing, albeit at moderating pace and to fewer car dealerships. That's the view from the US economy, which has so far proved mostly resilient in the face of a new Trump trade war and conflict in Europe and the Middle East.
That's not to say the economy isn't cooling. It is – we project GDP growth of 1.0% in the second half of the year, with a consumer-led slowdown the biggest risk to the outlook. As Fed Chair Jerome Powell has emphasized, when tariffs are imposed, someone ultimately bears the cost. We see it so far being borne mostly by the US side – mainly by firms via profit-margin compression, and only partly by consumers via higher consumer prices.
Euro-area GDP hit to worsen on higher tariffs, pharma threat
The chaos surrounding Trump's trade policies shows no sign of easing. The US has toughened its stance in trade negotiations, with President Trump issuing a new tariff threat of 30%. While negotiations between the EU and the US are expected to continue, it now seems unlikely that the pharmaceutical sector will dodge tariffs this year. In our updated projections, we have factored in a 25% tariff on pharma exports from the EU.
That shaves an additional 0.3% from the level of GDP – adding to the drag on growth, without adding up to a crash. When combined with more disinflationary pressures from weaker demand, it reinforces our view that the European Central Bank will move rates back below neutral. We forecast a terminal rate of 1.5%.
UK growth was volatile in 1H25, driven by the behavioral response of UK firms to an increase in US tariffs. The impact of higher levies on the level of output has so far been modest, though we think the drag is likely to intensify in 2H25 on the back of softer global growth. Domestic factors will likely play a larger role in shaping the outlook over the next 6-12 months. The labor market is loosening as a result of tepid demand and a rise in payroll tax. A further tightening of fiscal policy is likely in the autumn and will act as a headwind to growth next year and beyond.
We expect GDP to rise by 1.2% in 2025 and 1.1% in 2026. CPI inflation is likely to average 3.4% in 2025 and 2.4% in 2026. The BOE, meanwhile, is likely to lower rates to 3.75% in 2025,followed by one more 25-bp cut in 2026.
China growth above 5% target faces trade war reckoning
From AI breakthroughs to growth tracking above the 5% target, China's economy held up well in 1H25, considering all the challenges from a trade war to a sinking property market, low confidence, and deflation. We've raised our 2025 GDP projection to 4.8% from 4.6%. 2H25 will be a lot harder.
A reduction in US tariffs that breathed life back into exports and related sectors is scheduled to expire in mid-August. Consumption is slack beyond a lift from a trade-in program for home appliances and smartphones. Outside the tech sector, private investment continues to slide. Consumer prices are likely to fall this year for the first time since 2009. Monetary easing and faster fiscal delivery have put a floor under growth. Without additional stimulus, a sharp downturn in momentum later in the year looks likely.
Japan stagflationary risks rise as barriers to BOJ hikes pile up
Japan is facing stronger stagflationary pressures than it was a quarter ago. Inflation is on a higher path, buoyed by wage gains and rising price expectations. The BOJ is looking to pare stimulus. But gridlock in Japan-US trade talks and a surge in long-term JGB yields over concerns July's upper house election will open the door to fiscal expansion mean it's likely to stay on hold until October. This could weaken the yen, stoking inflation.
We've pushed back our call for a 25-bp rate hike to October from July. We've also lifted our core CPI inflation forecasts (excluding fresh food) to 3.4% for 2025 and 2.7% for 2026 (from 2.9% and 1.6%). With consumption under pressure from the cost-of-living squeeze, we now expect real GDP growth of 0.8% in 2025 and 0.5% in 2026 – down from our previous forecasts of 1.0% and 0.6%.
India may clock 7% growth on RBI rate cuts, interim US deal
India's economy is set to start rebounding in the current fiscal year after a drubbing last year from tight domestic policies. Among the key factors that support our projection are: the Reserve Bank's rate cuts since February, strong rural growth prospects due to surplus monsoon rains expected this year, and broad expectation of an impending interim trade deal with the US that may offer India better terms than to its rivals. We will revisit our call, depending on the out come of tariff negotiations.
We see growth rebounding to 7.0% in fiscal 2026 – which started in April – from 6.5% in fiscal 2025. The fuller impact of monetary easing and expected progress on trade agreements with the US and EU is likely to play out in fiscal 2027, when we expect growth to recover more strongly to 7.7%. Click the Text tab for the full report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns
NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns

Yahoo

time3 minutes ago

  • Yahoo

NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the NeuroScientific Biopharmaceuticals Limited (ASX:NSB) share price is up a whopping 576% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 410% gain in the last three months. The longer term returns have not been as good, with the stock price only 6.4% higher than it was three years ago. We love happy stories like this one. The company should be really proud of that performance! On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last year NeuroScientific Biopharmaceuticals grew its earnings per share (EPS) by 54%. The share price gain of 576% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 70.06 also points to this optimism. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). This free interactive report on NeuroScientific Biopharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. A Different Perspective We're pleased to report that NeuroScientific Biopharmaceuticals shareholders have received a total shareholder return of 576% over one year. That's better than the annualised return of 1.2% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with NeuroScientific Biopharmaceuticals (including 2 which are potentially serious) . For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump: Aug. 1 tariff deadline ‘stands strong'
Trump: Aug. 1 tariff deadline ‘stands strong'

Yahoo

time31 minutes ago

  • Yahoo

Trump: Aug. 1 tariff deadline ‘stands strong'

President Trump on Wednesday indicated there would be no extensions of the deadline at the end of the week, when steep tariffs are set to go into effect on many nations. 'The August first deadline is the August first deadline — It stands strong, and will not be extended. A big day for America!!!' Trump posted on Truth Social. Trump has issued letters to more than a dozen countries informing them of tariff rates they will face to export their goods into the United States beginning Aug. 1. Those include a 25 percent tariff on India, a 35 percent tariff on Bangladesh and a 50 percent tariff on Brazil, among others. The White House has struck deals with a handful of other countries to set lower tariff rates, including with Japan, the European Union, Indonesia and the United Kingdom. Critics have argued the details around those agreements are still scarce and have noted that the tariff rate those countries will pay, while lower than an initial threat, is still higher than it was before Trump took office. The timing and severity of tariffs on other nations have been shifting targets since Trump took office, after he vowed on the campaign trail to aggressively impose duties on imports. He has repeatedly threatened tariffs on other nations, only to back off or delay their imposition. The president on April 2 announced 'reciprocal' tariffs on dozens of other countries, using trade deficits to help calculate the tariff rate. But a week later, he lowered those rates to 10 percent for 90 days as markets reacted negatively, giving time for negotiations. The 90-day window was set to expire in early July, only for Trump to set a new deadline of Aug. 1. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword

Trump says he's not ‘seeking' summit with Xi
Trump says he's not ‘seeking' summit with Xi

Yahoo

time31 minutes ago

  • Yahoo

Trump says he's not ‘seeking' summit with Xi

President Trump said that he is not looking for a summit with Chinese President Xi Jinping, pushing back on reporting that the tariff talks this week could set the groundwork for a meeting with his counterpart. 'The Fake News is reporting that I am SEEKING a 'Summit' with President Xi of China. This is not correct, I am not SEEKING anything!' Trump said on Truth Social. 'I may go to China, but it would only be at the invitation of President Xi, which has been extended. Otherwise, no interest! Thank you for your attention to this matter.' Talks between the U.S. and China are going on in Stockholm this week with Treasury Secretary Scott Bessent and his counterparts, which marks the third round of talks between the two nations. The meeting could set up an extended tariff truce, which could lead to a meeting with Trump and Xi later this year, NBC News reported. China and the U.S. are facing an Aug. 12 deadline following agreements announced in May and June that brought down mutually imposed triple-digit tariffs. For other trading partners, Trump has set an Aug. 1 deadline for the resumption of tariffs. 'We have a good relationship with China,' Trump said Monday. 'China's tough.' The president last month said Xi was 'extremely hard to make a deal' with and the two leaders have had a fraught relationship in recent years. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store